In Vomiting Nausifar MPS Tablet blocks the action of chemicals in the body that can make you feel or be sick. It is often used to prevent nausea and vomiting that may be caused due to some medicines or cancer treatment. This medicine helps you recover more comfortably from cancer treatments such as radiation therapy or chemotherapy. It is also effective at preventing nausea and vomiting after an operation (in adults only). The dose will depend on what you are being treated for but always take this medicine as it is prescribed.
It is unsafe to consume alcohol with Nausifar MPS Tablet.
Nausifar MPS Tablet is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.
Nausifar MPS Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Nausifar MPS Tablet may cause side effects which could affect your ability to drive. Nausifar MPS Tablet may cause drowsiness, dizziness, dyskinesia and dystonias which could affect the vision and may interfere with the ability to drive.
Nausifar MPS Tablet should be used with caution in patients with kidney disease. Dose adjustment of Nausifar MPS Tablet may be needed. Please consult your doctor.
Nausifar MPS Tablet is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Nausifar MPS Tablet may not be needed in these patients. Please consult your doctor.
If you miss a dose of Nausifar MPS Tablet, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Wallace Pharmaceuticals Pvt Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Cosme Healthcare || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Ipca Laboratories Ltd || ₹14.5/tablet (25% cheaper)